Antagonism of platelet-derived growth factor receptor in non - small cell lung cancer: Rationale and investigations

Clinical Cancer Research

Volumn 13, Issue 15, 2007, Pages

  Bauman, Julie E ^a   Eaton, Keith D ^a   Martins, Renato G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ETOPOSIDE; IMATINIB; IRINOTECAN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATINUM; SORAFENIB; SUNITINIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER INHIBITION; CLINICAL TRIAL; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; IMMUNE DEFICIENCY; INTERSTITIAL FLUID; LUNG NON SMALL CELL CANCER; NONHUMAN; PERICYTE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PERICYTES; PIPERAZINES; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 34547686118     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0212     Document Type: Article

References (32)

1. Ostman A, Heidin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 2001;80:1-38.
2. Betsholtz C, Johnsson A, Heldin CH, et al. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines. Nature 1986;320:695-9.
3. George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol 2001;28:27-33.
4. Kaur H, Park CS, Lewis JM, Haugh JM. Quantitative model of Ras-phosphoinositide 3-kinase signaling cross-talk based on cooperative molecular assembly. Biochem J 2006;393:235-43.
5. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol 2005;23:866-73.
6. Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005;23:9359-68.
7. Raymond E, Brandes A, Van Oosterom A, et al. Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC/NDDG/BTG Intergroup study. J Clin Oncol 2004;22:abstract 1501.
8. Sinibaldi VJ, Carducci MA, Elza-Brown K, et al. A phase II evaluation of imatinib mesylate in stage M0 prostate cancer patients on hormonal therapy with evidence of biochemical relapse. J Clin Oncol 2006;24:abstract 14612.
9. Mathew P, Thall PF, Johnson MM, et al. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer and bone metastases. J Clin Oncol 2006;24:abstract 4562.
10. Shikada Y, Yonemitsu Y, Koga T, et al. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non - small cell lung carcinomas. Cancer Res 2005;65:7241-8.
11. Kawai T, Hiroi S, Torikata C. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 1997;77:431-6.
12. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:58-65.
13. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res1987;47:3039-51.
14. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13.
15. Shao, ZM, Nguyen M, Barsky SH. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 2000;19:4337-45.
16. Milosevic M, Fyles A, Hedley D, et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 2001;61:6400-5.
17. Rodt SA, Ahlen K, Berg A, Rubin K, Reed RK. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J Physiol 1996;495:193-200.
18. Pietras K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-34.
19. Pietras K, Stumm M, Hubert M, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003;9:3779-87.
20. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84.
21. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
22. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
23. Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development 1999;126:1149-59.
24. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65.
25. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998;125:1591-8.
26. Hirschi K, D'Amore P. Pericytes in themicrovasculature. Cardiovasc Res 1996;32:687-98.
27. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000.
28. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
29. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-52.
30. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
31. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-32.
32. George D. Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology 2002;60:115-22.